Chemoradiotherapy for Locally Recurrent Rectal Cancer
Author Information
Author(s): Lee Joo Ho, Kim Dae Yong, Kim Sun Young, Park Ji Won, Choi Hyo Seong, Oh Jae Hwan, Chang Hee Jin, Kim Tae Hyun, Park Suk Won
Primary Institution: National Cancer Center, Goyang, Korea
Hypothesis
To assess the clinical outcome of chemoradiotherapy with or without surgery for locally recurrent rectal cancer and to find significant prognostic factors.
Conclusion
Chemoradiotherapy with or without surgery could be a potential option for curing locally recurrent rectal cancer, with symptoms being a significant prognostic factor for poor outcomes.
Supporting Evidence
- The median survival duration of all patients was 59 months.
- Five-year overall survival was 48.9%.
- Symptoms related to local recurrence were significant prognostic factors.
Takeaway
Doctors are trying to find the best way to treat patients with rectal cancer that comes back after treatment, and they found that using a mix of chemotherapy and radiation can help.
Methodology
67 patients with locally recurrent rectal cancer were treated with chemoradiotherapy with or without surgery, and their outcomes were reviewed retrospectively.
Potential Biases
Potential biases due to retrospective design and selection of patients for treatment.
Limitations
The study had a small sample size and a heterogeneous population, which may affect the generalizability of the results.
Participant Demographics
{"median_age":57,"gender_distribution":{"male":40,"female":27}}
Statistical Information
P-Value
{"os":0.181,"rfs":0.113,"lrfs":0.379,"dmfs":0.335}
Confidence Interval
{"os":"1.17-10.22","rfs":"1.22-7.59","lrfs":"1.48-8.80","dmfs":"1.10-7.89"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website